Karen E. Knudsen

Add links
Source: Wikipedia, the free encyclopedia.

Karen E. Knudsen is Chief Executive Officer of American Cancer Society and its advocacy affiliate the American Cancer Society Cancer Action Network. She is the first woman to hold that position in either organization.[1]

Prior to joining ACS, Dr. Knudsen served as Executive Vice President of Oncology Services, Jefferson Health and Enterprise Director of its Sidney Kimmel Comprehensive Cancer Center, one of 71 NCI-designated cancer centers in the United States. Previously she was the Hilary Koprowski Endowed Professor of Oncology at Thomas Jefferson University in Philadelphia, Pennsylvania. She also held secondary appointments in the Departments of Urology, Medical Oncology, and Radiation Oncology.

Education and career

Knudsen received her bachelor’s degree in biology from the

University of Cincinnati College of Medicine
in 2000, wherein she became a tenured Associate Professor.

In 2007 she joined the Sidney Kimmel Cancer Center at Jefferson Health, and founded the cancer center’s prostate cancer program. After serving as the Deputy Director of the Sidney Kimmel Cancer Center and the Vice Provost of Thomas Jefferson University, Knudsen accepted the offer to serve as the Enterprise Director of the Sidney Kimmel Cancer Center in 2015, leading the cancer care and cancer discovery mission for Jefferson Health. She is also editor-in-chief, Molecular Cancer Research[2]

Dr. Knudsen currently holds leadership roles with some of the most important cancer entities in the nation. She serves on the board of advisors for the

American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards. She previously served as president of the Association of American Cancer Institutes (AACI), representing the 102 leading cancer centers in North America, and on the board of directors of the American Association for Cancer Research (AACR). Dr. Knudsen was also recognized as one of the 100 Influential Women in Oncology by OncoDaily.[3]

Research

Knudsen is an

precision medicine in advanced prostate cancer, with an emphasis on understanding therapeutic relapse and designing new means of clinical intervention. Her translational studies have resulted in new clinical trials targeting DNA repair, cell cycle, and hormonal regulation pathways in patients with advanced disease. Knudsen and her colleagues discovered the mechanisms by which androgen signaling impacts cancer cell proliferation and DNA repair processes, and identified novel strategies for therapeutic intervention. Notable discoveries include identification of RB tumor suppressor loss as a major mechanism of therapeutic bypass,[4][5][6] discovery of the androgen-DNA repair axis,[7][8][9] and elucidation of androgen receptor function in the mitotic cell cycle.[10][11][12] Her discoveries were amongst the first to propose utilization of PARP 1/2 inhibitors for advanced disease,[13][14][15] now an FDA-approved agent for selected prostate cancers.[16]

Service

References

  1. ^ "American Cancer Society Names Dr. Karen Knudsen as its Next CEO". cancer.org. American Cancer Society. Retrieved 8 June 2021.
  2. ^ "Editorial Board | Molecular Cancer Research". mcr.aacrjournals.org. Retrieved 2020-11-27.
  3. ^ "100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2023". OncoDaily.
  4. PMID 17616676
    .
  5. PMID 21099110
    .
  6. PMID 29202480
    .
  7. PMID 24027197
    .
  8. PMID 26175416
    .
  9. PMID 31266833
    .
  10. PMID 16461912
    .
  11. PMID 23257359
    .
  12. PMID 29739788
    .
  13. PMID 22993403
    .
  14. PMID 26091341
    .
  15. PMID 30467127
    .
  16. ^ Research, Center for Drug Evaluation and (2020-05-20). "FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer". FDA.
  17. ^ "AACI President Knudsen to Focus Two-Year Term on Mitigating Health Disparities". www.newswise.com. Retrieved 2021-01-08.
  18. ^ "Board of Directors | AACR About Us". American Association for Cancer Research (AACR). Retrieved 2021-01-08.
  19. ^ "NCI Board of Scientific Advisors". deainfo.nci.nih.gov. Retrieved 2020-11-27.
  20. ^ "Genentech: Scientific Research Board". www.gene.com. Retrieved 2020-11-27.
  21. ^ "Editorial Board | Molecular Cancer Research". mcr.aacrjournals.org. Retrieved 2020-11-27.
  22. ^ "About the Editors | Oncogene". www.nature.com. Retrieved 2020-11-27.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Karen_E._Knudsen&oldid=1184278799"